Association of baseline advanced HIV disease and dolutegravir versus non-dolutegravir regimen status with viral load suppression among patients on antiretroviral therapy in Tanzania

In a retrospective cohort study of Tanzanian patients on antiretroviral therapy, dolutegravir-based regimens were associated with improved viral load suppression overall, with a particularly significant relative benefit observed among patients presenting with baseline advanced HIV disease.

The Gist

Imagine the fight against HIV as a massive, nationwide marathon in Tanzania. The runners are patients taking medication (antiretrovirals) to keep the virus in check. The goal of the race is to reach the finish line with a "clean" blood test, meaning the virus is undetectable. This state is called viral suppression.

For a long time, runners had different types of shoes (medication regimens). Some were older, heavier shoes, while others were new, high-tech sneakers called Dolutegravir (DTG). The new shoes are known to be faster, more comfortable, and harder to break.

However, not all runners start the race in the same condition. Some start fresh and healthy, while others start the race already exhausted and injured. In medical terms, these "exhausted" runners have Advanced HIV Disease (AHD), meaning their immune systems (their body's defense team) were already very weak when they began treatment.

This study looked at the race results for nearly 4,000 runners in Tanzania to answer two big questions:

1. Does starting the race with a weak immune system hurt your chances of finishing strong?
2. Do the new "DTG sneakers" help everyone, or do they help the injured runners the most?

The Big Findings

1. The Race is Going Well Overall
The good news is that the race is going very well. About 89% of the runners crossed the finish line with a clean bill of health. This shows that the Tanzanian healthcare system is doing a great job getting people on medication and keeping them there.

2. The "Exhausted" Runners Struggle More
The study found that runners who started with Advanced HIV Disease (AHD) had a harder time. Only about 81% of them reached the finish line successfully, compared to 91% of those who started healthy.

• The Analogy: Imagine trying to run a marathon while carrying a heavy backpack (the virus and a weak immune system). Even with good shoes, it's much harder to run fast and finish strong. These runners need extra support, like a personal trainer or a lighter backpack, to catch up.

3. The New Shoes (DTG) Are a Game-Changer
Runners wearing the new DTG shoes finished the race much more successfully than those in the old shoes.

• Old Shoes: Only about 77% finished strong.
• New DTG Shoes: About 91.5% finished strong.
• The Analogy: The new shoes are like a turbo boost. They are more powerful and keep the virus from fighting back, making it much easier to win the race.

4. The Magic Combo: DTG + The Injured
Here is the most exciting discovery: The new DTG shoes didn't just help everyone a little; they helped the injured runners the most.

• Runners with Advanced HIV who wore the old shoes had a very hard time (only 55% succeeded).
• But runners with Advanced HIV who wore the new DTG shoes saw their success rate jump to 87%.
• The Analogy: It's like giving a super-powered exoskeleton to a runner who is already injured. While a healthy runner might just walk faster with it, the injured runner goes from barely moving to running at full speed. The new medicine bridges the gap for the most vulnerable patients.

What Does This Mean for Real Life?

The researchers are saying three important things to the doctors and policymakers:

1. Keep Buying the New Shoes: The country should continue to prioritize the DTG medication because it works incredibly well, especially for the sickest patients.
2. Check the Backpacks Early: Even though doctors now treat everyone immediately after diagnosis (without waiting), they still need to check how "heavy the backpack" is (the CD4 count) right at the start. If a patient is already very sick, they need extra attention, not just the standard care.
3. Find the Runners Sooner: The best way to help is to find people before they get to the point of being "exhausted." The sooner they start the race, the less likely they are to need a rescue.

The Bottom Line

Tanzania is winning the war against HIV, with most patients doing very well. However, the patients who start the treatment when they are already very sick face a tougher battle. The new DTG medication is a powerful tool that helps level the playing field, giving the sickest patients their best chance at a healthy life. It's a reminder that while the medicine is strong, we must also pay special attention to those who are most vulnerable.

Technical Summary

Title

Association of baseline advanced HIV disease and dolutegravir versus non-dolutegravir regimen status with viral load suppression among patients on antiretroviral therapy in Tanzania.

1. Problem Statement

Despite the global scale-up of antiretroviral therapy (ART) and the transition to Dolutegravir (DTG)-based regimens as the preferred first-line treatment, significant disparities in treatment outcomes persist. Specifically, patients presenting with Advanced HIV Disease (AHD) (defined as CD4+ <200 cells/µL or WHO clinical stage 3/4) face higher risks of mortality and virologic failure. While DTG is known for high potency and a high genetic barrier to resistance, it remains unclear whether its benefits are uniform across all patient subgroups, particularly those with severe immunosuppression, within routine national care settings in sub-Saharan Africa. There is a lack of evidence from large-scale routine data regarding the joint influence of baseline AHD and regimen type (DTG vs. non-DTG) on viral load suppression in Tanzania.

2. Methodology

• Study Design: Retrospective cohort analysis using routine programmatic data.
• Data Source: The National AIDS, STIs, and Hepatitis Control Programme (NASHCoP) master database in Tanzania, covering the period 2017–2021.
• Sampling Strategy:
  • A simple random sample of 50,000 unique patients was drawn from the de-duplicated national dataset.
  • After data processing and linkage, the working dataset contained 49,863 patients.
  • Inclusion Criteria: Patients with both a non-missing baseline CD4 count (at ART initiation) and a non-missing endpoint viral load result.
  • Final Analytic Cohort: 4,044 patients.
• Variables:
  • Primary Outcome: Viral load suppression, defined as <1,000 copies/mL.
  • Exposures:
    • Baseline AHD status (CD4 <200 cells/µL vs. ≥200 cells/µL).
    • Regimen status (DTG-based vs. non-DTG-based).
  • Covariates: Age, gender, follow-up duration, adherence (derived from visit patterns), and therapy change count.
• Statistical Analysis:
  • Unadjusted associations calculated using Risk Ratios (RR).
  • Adjusted analyses performed using Generalized Linear Models (GLM) with a Poisson distribution and log link to estimate Adjusted Risk Ratios (aRR).
  • Models included main effects and an interaction term between AHD and DTG regimen status to assess if the benefit of DTG varied by AHD status.
  • Robust variance estimation was used to account for overdispersion.

3. Key Contributions

• Real-World Evidence: Provides one of the largest analyses of routine care data in Tanzania examining the intersection of AHD and DTG adoption.
• Interaction Analysis: Specifically investigates the synergistic effect of DTG regimens on patients with advanced disease, moving beyond simple main-effect comparisons.
• Policy Relevance: Validates the utility of baseline CD4 testing for risk stratification even in the "test-and-treat" era, where universal CD4 testing is sometimes de-emphasized.

4. Key Results

• Overall Suppression: The overall viral load suppression rate in the cohort was 89.2% (3,607/4,044).
• Impact of AHD:
  • Patients with baseline AHD had significantly lower suppression rates (81.3%) compared to those without AHD (91.1%).
  • Unadjusted RR: 0.48 (95% CI: 0.40–0.57).
  • Adjusted RR (aRR): 0.89 (95% CI: 0.86–0.92), indicating AHD remains an independent predictor of failure.
• Impact of DTG Regimens:
  • Patients on DTG regimens had higher suppression (91.5%) than those on non-DTG regimens (77.2%).
  • Unadjusted RR: 2.67 (95% CI: 2.23–3.20).
  • Adjusted RR (aRR): 1.15 (95% CI: 1.10–1.20).
• Stratified Analysis (Combined Effects):
  • No AHD + DTG: Highest suppression (92.5%).
  • AHD + DTG: High suppression (87.2%).
  • No AHD + Non-DTG: Moderate suppression (83.6%).
  • AHD + Non-DTG: Lowest suppression (55.2%).
• Interaction Effect:
  • A statistically significant interaction was found between AHD and DTG (aRR 1.40; 95% CI: 1.20–1.63).
  • Interpretation: The relative benefit of switching to or using a DTG-based regimen is greater for patients with baseline AHD compared to those without. DTG appears to partially mitigate the adverse impact of severe immunosuppression on treatment outcomes.
• Other Factors: Higher adherence was positively associated with suppression, while a higher number of therapy changes was negatively associated.

5. Significance and Implications

• Clinical Strategy: The findings strongly support the prioritization of DTG-based regimens as the backbone of first-line ART, particularly for patients presenting with advanced disease. DTG offers a critical protective effect for this vulnerable subgroup.
• Programmatic Policy:
  • Early Diagnosis: There is an urgent need to expand HIV testing and linkage to care to reduce the number of patients initiating ART with AHD.
  • Risk Stratification: Baseline CD4 testing should be maintained as a tool for identifying high-risk patients (AHD) who require intensified monitoring and adherence support, even in universal test-and-treat programs.
  • Targeted Management: Patients with AHD on non-DTG regimens are at extreme risk of failure; rapid transition to DTG and enhanced clinical follow-up are recommended.
• Limitations: The study relies on retrospective routine data with potential missingness (only ~8% of the initial sample had complete CD4 and viral load data), which may introduce selection bias. Confounding by unmeasured socioeconomic factors or comorbidities cannot be fully excluded.

Conclusion: While Tanzania has achieved high overall viral suppression rates, patients with baseline AHD remain a high-risk group. DTG-based regimens significantly improve outcomes for all patients but provide a disproportionately larger benefit to those with advanced disease, reinforcing the need for early diagnosis and targeted management strategies.